Raymond James & Associates increased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 26.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,315,255 shares of the company's stock after acquiring an additional 491,498 shares during the period. Raymond James & Associates owned about 0.09% of Sanofi worth $112,521,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Rise Advisors LLC increased its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company's stock worth $25,000 after purchasing an additional 251 shares during the period. Salem Investment Counselors Inc. purchased a new stake in Sanofi during the 4th quarter worth about $27,000. Venturi Wealth Management LLC increased its holdings in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company's stock worth $27,000 after purchasing an additional 332 shares during the period. Frazier Financial Advisors LLC purchased a new stake in Sanofi during the 4th quarter worth about $28,000. Finally, Register Financial Advisors LLC purchased a new position in shares of Sanofi in the 1st quarter valued at about $29,000. Institutional investors and hedge funds own 10.04% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on SNY shares. Morgan Stanley started coverage on Sanofi in a report on Tuesday, January 23rd. They issued an "equal weight" rating and a $55.00 price objective on the stock. TheStreet downgraded Sanofi from a "b" rating to a "c" rating in a report on Friday, February 9th. Finally, StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a report on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $55.00.
Read Our Latest Stock Analysis on Sanofi
Sanofi Stock Performance
Sanofi stock traded up $0.80 during mid-day trading on Wednesday, reaching $50.03. 1,363,462 shares of the company were exchanged, compared to its average volume of 2,017,410. Sanofi has a twelve month low of $42.63 and a twelve month high of $55.93. The firm's 50-day simple moving average is $47.86 and its two-hundred day simple moving average is $48.26. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a market cap of $126.56 billion, a PE ratio of 25.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. Equities analysts predict that Sanofi will post 4.11 earnings per share for the current fiscal year.
Sanofi Increases Dividend
The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.38. This represents a yield of 2.98%. Sanofi's payout ratio is currently 73.87%.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
